ZYTOPROTEC AT A GLANCE
Our mission is to make a novel therapeutic approach a reality in PD – an area where clinicians and patients saw disappointingly little innovation in decades.
Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial in 2022.
The Company is lead by a management team that combines extensive expertise in the renal business, in financing and Venture Capital, as well as in nephrology and clinical development.
MANAGEMENT
- With Zytoprotec since 2014
- Managing Director since November 2015
Prior Experience:
- Over 20 years of expertise in biotech-related venture capital
- Between 1993-2010, general partner and CFO of TVM Capital, a European venture firm
- Managed and structured more than 100 transactions at TVM, including financings, acquisitions and IPOs
- With Zytoprotec since 2015
- Managing Director since November 2015
Prior Experience:
- Joined as Managing Director in November 2015
- Over 20 years experience in the hospital and renal business acting in various management capacities
- In 1997, he sold InfusMedizintechnikas its Managing Director to Baxter
- Occupied several functions within Baxter thereafter, most recently General Manager for Baxter and Gambro-Renal, Austria
- Co-founder of Zytoprotec
- Chief Scientific Officer
Prior Experience:
- Professor of pediatric nephrology and gastroenterology at Medical University of Vienna and Head of division pediatric nephrology and gastroenterology at the department of pediatrics and adolescent medicine
- Has conducted research at Yale and UCLA and teaches medicine at Medical University of Vienna
- Author of more than 100 scientific articles in journals and books and regular speaker at dialysis
Head of Research
Clinical Expert
Key Milestones
2019 Participation in EU Horizon 2020 project Improve-PD
2017 FDA grants Orphan Drug Designation to PDprotec®
2017 Results of Phase II trial of PDprotec®: Outstanding safety and efficacy profile
2016/17 Series A2 Financing
2016 Zytoprotec opens laboratory for biomarker research in PD
2015 Double-blinded, placebo-controlled Phase II trial of PDprotec® initiated
2013 Series A Financing
2012 EPO grants patent for PDprotec®
2012 Phase I/II trial with PDprotec® completed
2011 First financing with private investors
2007 Zytoprotec founded
PARTNERS & COOPERATIONS
